

Sindhu R Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7463912/publications.pdf>

Version: 2024-02-01

143
papers

11,457
citations

61984

43
h-index

30922

102
g-index

145
all docs

145
docs citations

145
times ranked

10534
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
3	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
5	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	3.4	466
6	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	3.4	386
7	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	5.6	339
8	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12.	5.6	201
9	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021, 73, 1093-1107.	5.6	146
10	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	5.6	142
11	Methods to elicit beliefs for Bayesian priors: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 355-369.	5.0	140
12	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	6.7	134
13	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	3.4	129
14	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e60-e75.	5.6	126
15	Classification criteria in rheumatic diseases: A review of methodologic properties. <i>Arthritis and Rheumatism</i> , 2007, 57, 1119-1133.	6.7	122
16	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	5.6	110
17	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. <i>Arthritis and Rheumatology</i> , 2019, 71, 91-98.	5.6	93
18	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581.	3.4	91

#	ARTICLE	IF	CITATIONS
19	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	3.4	77
20	Warfarin in Systemic Sclerosis-associated and Idiopathic Pulmonary Arterial Hypertension. A Bayesian Approach to Evaluating Treatment for Uncommon Disease. <i>Journal of Rheumatology</i> , 2012, 39, 276-285.	2.0	75
21	Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma. <i>Journal of Rheumatology</i> , 2009, 36, 323-329.	2.0	71
22	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
23	EVOLUTION AND OUTCOMES OF A RAPID RESPONSE TEAM. <i>Chest</i> , 2006, 130, 218S.	0.8	68
24	The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: An evaluation of their measurement properties. <i>Arthritis and Rheumatism</i> , 2005, 53, 256-262.	6.7	67
25	A valid and reliable belief elicitation method for Bayesian priors. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 370-383.	5.0	66
26	Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0124205.	2.5	66
27	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	5.6	64
28	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.7	62
29	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e30-e45.	5.6	61
30	Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. <i>Journal of Rheumatology</i> , 2006, 33, 1117-22.	2.0	60
31	Magnetic Resonance Imaging of the Hand in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 961-964.	2.0	57
32	The Effect of Male Sex on Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 2193-2200.	2.0	56
33	Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 203-213.	1.9	56
34	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
35	Biologic Therapy for Systemic Sclerosis: A Systematic Review. <i>Journal of Rheumatology</i> , 2011, 38, 289-296.	2.0	52
36	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52

#	ARTICLE	IF	CITATIONS
37	Classifying and diagnosing systemic lupus erythematosus in the 21st century. <i>Rheumatology</i> , 2020, 59, v4-v11.	1.9	52
38	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	5.6	52
39	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.9	51
40	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	3.4	49
41	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. <i>Arthritis and Rheumatology</i> , 2022, 74, e21-e36.	5.6	49
42	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1488-1494.	3.4	48
43	Response to: "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus" by Aringer et al. by Cui et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e166-e166.	0.9	47
44	New ACR EULAR Guidelines for Systemic Sclerosis Classification. <i>Current Rheumatology Reports</i> , 2015, 17, 32.	4.7	46
45	Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement, and Mortality. <i>Journal of Rheumatology</i> , 2019, 46, 1103-1108.	2.0	46
46	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 1990-5.	2.0	46
47	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	2.0	45
48	Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. <i>Journal of Rheumatology</i> , 2006, 33, 2347-50.	2.0	45
49	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.7	42
50	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
51	Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 174-182.	3.4	39
52	New Criteria for Lupus. <i>Current Rheumatology Reports</i> , 2020, 22, 18.	4.7	37
53	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
54	Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. <i>Journal of Rheumatology</i> , 2018, 45, 1406-1410.	2.0	36

#	ARTICLE	IF	CITATIONS
55	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
56	Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 41.	3.5	34
57	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
58	Classification criteria for systemic sclerosis subsets. <i>Journal of Rheumatology</i> , 2007, 34, 1855-63.	2.0	34
59	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33
60	New Classification Criteria for Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 383-398.	1.9	32
61	Ethnic Influence on Disease Manifestations and Autoantibodies in Chinese-Descent Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 787-793.	2.0	31
62	Effect of Warfarin on Survival in Scleroderma-associated Pulmonary Arterial Hypertension (SSc-PAH) and Idiopathic PAH. Belief Elicitation for Bayesian Priors. <i>Journal of Rheumatology</i> , 2011, 38, 462-469.	2.0	30
63	Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 30.	3.5	28
64	Response to: "European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view" by Infantino et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e189-e189.	0.9	28
65	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	3.4	28
66	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. <i>Respiratory Medicine</i> , 2012, 106, 730-739.	2.9	26
67	The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 264.	3.5	26
68	Hydroxychloroquine shortages during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e31-e31.	0.9	26
69	Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review. <i>Journal of Rheumatology</i> , 2015, 42, 1432-1438.	2.0	22
70	Is self-reported improvement in osteoarthritis pain and disability reflected in objective measures?. <i>Journal of Rheumatology</i> , 2007, 34, 159-64.	2.0	22
71	New EULAR/ACR 2019 SLE Classification Criteria: defining omniosity in SLE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 767-774.	0.9	20
72	Scleroderma: health services utilization from patients' perspective. <i>Journal of Rheumatology</i> , 2006, 33, 1123-7.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	7.1	18
74	COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. <i>Journal of Rheumatology</i> , 2022, 49, 523-530.	2.0	18
75	Online obituaries are a reliable and valid source of mortality data. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 167-168.	5.0	17
76	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>Disability and Rehabilitation</i> , 2018, 40, 1997-2003.	1.8	17
77	Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. <i>Respirology</i> , 2015, 20, 481-487.	2.3	16
78	Controversies: molecular vs. clinical systemic sclerosis classification. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 277-285.	1.7	16
79	Unmet Workplace Support Needs and Lost Productivity of Workers With Systemic Sclerosis: A Path Analysis Study. <i>Arthritis Care and Research</i> , 2021, 73, 423-431.	3.4	15
80	Systemic Lupus Erythematosus Classification and Diagnosis. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 501-511.	1.9	15
81	Epidemiology and Treatment of Peripheral Neuropathy in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1839-1849.	2.0	14
82	Qualitative Methods in Systemic Sclerosis Research. <i>Journal of Rheumatology</i> , 2016, 43, 1265-1267.	2.0	13
83	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	3.4	13
84	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.7	13
85	Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 223.	3.5	13
86	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	0.6	13
87	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. <i>Rheumatology</i> , 2022, 62, 234-242.	1.9	13
88	Management of Calcinosis Cutis in Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2022, 49, 980-989.	2.0	13
89	Botulinum toxin in the management of primary and secondary Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101684.	3.3	12
90	Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease. <i>Canadian Respiratory Journal</i> , 2017, 2017, 1-8.	1.6	11

#	ARTICLE	IF	CITATIONS
91	Advances in SLE classification criteria. Journal of Autoimmunity, 2022, 132, 102845.	6.5	11
92	Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease. Journal of Rheumatology, 2014, 41, 2326-2328.	2.0	10
93	Factors Predictive of Radiographic Progression in Ankylosing Spondylitis. Arthritis Care and Research, 2021, 73, 275-281.	3.4	10
94	Evolving concepts in systemic lupus erythematosus damage assessment. Nature Reviews Rheumatology, 2021, 17, 307-308.	8.0	10
95	Progress in the clinical classification of systemic sclerosis. Current Opinion in Rheumatology, 2017, 29, 568-573.	4.3	9
96	Employment outcomes in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101667.	3.3	9
97	Venous Thromboembolism in Systemic Sclerosis: Prevalence, Risk Factors, and Effect on Survival. Journal of Rheumatology, 2018, 45, 942-946.	2.0	8
98	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. Lupus, 2021, 30, 867-875.	1.6	8
99	Understanding COVID-19 Risk in Patients with Immune Mediated Inflammatory Diseases: A Population-based analysis of SARS-CoV-2 Testing. Arthritis Care and Research, 2021, , .	3.4	8
100	New lupus criteria: a critical view. Current Opinion in Rheumatology, 2021, 33, 205-210.	4.3	8
101	Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. Expert Review of Clinical Immunology, 2022, 18, 135-144.	3.0	8
102	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. Rheumatology, 2021, 60, 1456-1464.	1.9	7
103	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	1.0	7
104	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
105	Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. Journal of Rheumatology, 2017, 44, 18-23.	2.0	6
106	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 321-325.	2.0	6
107	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
108	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Bossuyt et al. Annals of the Rheumatic Diseases, 2023, 82, e194-e194.	0.9	6

#	ARTICLE	IF	CITATIONS
109	Bayesian Inference: Statistical Gimmick or Added Value?. <i>Journal of Rheumatology</i> , 2011, 38, 794-796.	2.0	4
110	Applied Bayesian Methods in the Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 361-370.	1.9	4
111	Difference between SLE classification and diagnosis and importance of attribution. Response to: "Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?" by Chi et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrhumdis-2019-216338.	0.9	4
112	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	3.4	4
113	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	1.6	4
114	Inflammatory Arthritis, Sacroiliitis, and Morphea: Evidence of a Systemic Inflammatory Disease. <i>Case Reports in Rheumatology</i> , 2013, 2013, 1-3.	0.6	3
115	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	2.0	3
116	Use of "Provisional" Designation for Response Criteria. <i>Arthritis Care and Research</i> , 2018, 70, 811-812.	3.4	3
117	Response to: "New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion" by Sacre et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e191-e191.	0.9	3
118	Response to: "Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?" by Teng et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e23-e23.	0.9	3
119	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	1.2	3
120	Advanced Epidemiologic Methods for the Study of Rheumatic and Musculoskeletal Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, xv-xvi.	1.9	2
121	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 696-697.	3.4	2
122	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1769-1770.	5.6	2
123	Effectiveness of initial methotrexate-based treatment approaches in early rheumatoid arthritis: an elicitation of rheumatologists' beliefs. <i>Rheumatology</i> , 2021, 60, 3570-3578.	1.9	2
124	Response to: "Correspondence on "Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities" by Ronnelid et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219314.	0.9	2
125	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1049-1050.	3.4	1
126	Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 115-126.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Response to: "New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS" by Assan et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrhumdis-2019-216250.	0.9	1
128	Classification of IgG4-Related Disease: A Medical Marvel of Our Time. <i>Arthritis and Rheumatology</i> , 2020, 72, 1-3.	5.6	1
129	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 695-696.	5.6	1
130	Current Therapeutic Approaches in Scleroderma: Clinical Models of Effective Antifibrotic Therapies. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 382-393.	1.4	1
131	Diagnosis and Classification of Systemic Lupus Erythematosus. , 2021, , 51-66.		1
132	Response to: "Role of ANA testing in the classification of patients with systemic lupus erythematosus" by Pisetsky et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e125-e125.	0.9	1
133	How the American College of Rheumatology Develops Guidelines. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 579-588.	1.9	1
134	Peter Lee, MD, FRCPC, FRACP, 1943-2014. <i>Journal of Rheumatology</i> , 2014, 41, 2490-2490.	2.0	0
135	AI-09...T follicular helper (Tfh) cells are increased in asymptomatic anti-nuclear antibody (ANA)+ individuals and appear to play a role in epitope spreading. , 2018, , .		0
136	Response to: "Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus" by Wang et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrhumdis-2019-216807.	0.9	0
137	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 860-861.	5.6	0
138	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1404-1404.	5.6	0
139	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 548-549.	5.6	0
140	Developing a pulmonary hypertension health passport to improve care: A qualitative study. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 0, , 1-6.	0.5	0
141	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousity in SLE" by Whittall Garcia et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-221014.	0.9	0
142	Innovations in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101708.	3.3	0
143	Intrathoracic arteritis: a paraneoplastic presentation of malignant melanoma. <i>Journal of Rheumatology</i> , 2006, 33, 820-1.	2.0	0